2023
DOI: 10.1093/ecco-jcc/jjac190.0630
|View full text |Cite
|
Sign up to set email alerts
|

P500 Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients.

Abstract: Background Ustekinumab has been recently approved for the treatment of moderately to severe ulcerative colitis (UC). Data from the UNIFI clinical trial are encouraging; nevertheless, real-world assessment is needed. We assess the effectiveness, safety and pharmacokinetics of ustekinumab in a cohort of refractory UC patients. Methods Multicentre and observational study of UC patients who received ustekinumab for active disease… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles